A decline in PABPN1 induces progressive muscle weakness in Oculopharyngeal muscle dystrophy and in muscle aging

被引:39
|
作者
Anvar, Seyed Yahya [1 ]
Raz, Yotam [2 ]
Verwey, Nisha [1 ]
van der Sluijs, Barbara [4 ]
Venema, Andrea [1 ]
Goeman, Jelle J. [3 ]
Vissing, John [5 ,6 ]
van der Maarel, Silvere M. [1 ]
't Hoen, Peter A. C. [1 ]
van Engelen, Baziel G. M. [4 ]
Raz, Vered [1 ]
机构
[1] Leiden Univ, Ctr Human & Clin Genet, Med Ctr, Leiden, Netherlands
[2] Leiden Univ, Med Ctr, Dept Gerontol & Geriatr, Leiden, Netherlands
[3] Leiden Univ, Med Ctr, Dept Med Stat & Bioinformat, Leiden, Netherlands
[4] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Nijmegen, Netherlands
[5] Rigshosp Copenhagen, Neuromuscular Res Unit, Copenhagen, Denmark
[6] Rigshosp Copenhagen, Dept Neurol, Copenhagen, Denmark
来源
AGING-US | 2013年 / 5卷 / 06期
关键词
Type; 2; diabetes; TCF7L2; centenarians; extreme phenotypes; age-related diseases; NUCLEAR POLY(A)-BINDING PROTEIN; UBIQUITIN-PROTEASOME SYSTEM; MUSCULAR-DYSTROPHY; MOUSE MODEL; DISEASES; AGGREGATION; INCLUSIONS; EXPRESSION; TOXICITY; REORGANIZATION;
D O I
10.18632/aging.100567
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Oculopharyngeal muscular dystrophy (OPMD) is caused by trinucleotide repeat expansion mutations in Poly(A) binding protein 1 (PABPN1). PABPN1 is a regulator of mRNA stability and is ubiquitously expressed. Here we investigated how symptoms in OPMD initiate only at midlife and why a subset of skeletal muscles is predominantly affected. Genome-wide RNA expression profiles from Vastus lateralis muscles human carriers of expanded-PABPN1 at pre-symptomatic and symptomatic stages were compared with healthy controls. Major expression changes were found to be associated with age rather than with expression of expanded-PABPN1, instead transcriptomes of OPMD and elderly muscles were significantly similar (P<0.05). Using k-means clustering we identified age-dependent trends in both OPMD and controls, but trends were often accelerated in OPMD. We report an age-regulated decline in PABPN1 levels in Vastus lateralis muscles from the fifth decade. In concurrence with severe muscle degeneration in OPMD, the decline in PABPN1 accelerated in OPMD and was specific to skeletal muscles. Reduced PABPN1 levels (30% to 60%) in muscle cells induced myogenic defects and morphological signatures of cellular aging in proportion to PABPN1 expression levels. We suggest that PABPN1 levels regulate muscle cell aging and OPMD represents an accelerated muscle aging disorder.
引用
收藏
页码:412 / 426
页数:15
相关论文
共 50 条
  • [1] Muscle-specific PABPN1 regulation in Oculopharyngeal muscular dystrophy
    Phillips, B. L.
    Apponi, L. H.
    Choo, H.
    Vest, K. E.
    Pavlath, G. K.
    Corbett, A. H.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [2] Oculopharyngeal muscle dystrophy: fine structure and mRNA expression levels of PABPN1
    Schroeder, J. M.
    Klossok, T.
    Weis, J.
    CLINICAL NEUROPATHOLOGY, 2011, 30 (03) : 94 - 103
  • [3] Muscle Weakness and Speech in Oculopharyngeal Muscular Dystrophy
    Neel, Amy T.
    Palmer, Phyllis M.
    Sprouls, Gwyneth
    Morrison, Leslie
    JOURNAL OF SPEECH LANGUAGE AND HEARING RESEARCH, 2015, 58 (01): : 1 - 12
  • [4] Mitochondrial localization of PABPN1 in oculopharyngeal muscular dystrophy
    Doki, Tsukasa
    Yamashita, Satoshi
    Wei, Fan-Yan
    Hara, Kentaro
    Yamamoto, Takahiro
    Zhang, Ziwei
    Zhang, Xiao
    Tawara, Nozomu
    Hino, Hirotake
    Uyama, Eiichiro
    Kurashige, Takashi
    Maruyama, Hirofumi
    Tomizawa, Kazuhito
    Ando, Yukio
    LABORATORY INVESTIGATION, 2019, 99 (11) : 1728 - 1740
  • [5] PABPN1 gene therapy for oculopharyngeal muscular dystrophy
    Malerba, A.
    Klein, P.
    Bachtarzi, H.
    Jarmin, S. A.
    Cordova, G.
    Ferry, A.
    Strings, V.
    Espinoza, M. Polay
    Mamchaoui, K.
    Blumen, S. C.
    St Guily, J. Lacau
    Mouly, V.
    Graham, M.
    Butler-Browne, G.
    Suhy, D. A.
    Trollet, C.
    Dickson, G.
    NATURE COMMUNICATIONS, 2017, 8
  • [6] PABPN1: molecular function and muscle disease
    Banerjee, Ayan
    Apponi, Luciano H.
    Pavlath, Grace K.
    Corbett, Anita H.
    FEBS JOURNAL, 2013, 280 (17) : 4230 - 4250
  • [7] PABPN1 gene therapy for oculopharyngeal muscular dystrophy
    A. Malerba
    P. Klein
    H. Bachtarzi
    S. A. Jarmin
    G. Cordova
    A. Ferry
    V. Strings
    M. Polay Espinoza
    K. Mamchaoui
    S. C. Blumen
    J. Lacau St Guily
    V. Mouly
    M. Graham
    G. Butler-Browne
    D. A. Suhy
    C. Trollet
    G. Dickson
    Nature Communications, 8
  • [8] Functional impact of an oculopharyngeal muscular dystrophy mutation in PABPN1
    Garcia-Castaneda, Maricela
    Victoria Vega, Ana
    Rodriguez, Rocio
    Guadalupe Montiel-Jaen, Maria
    Cisneros, Bulmaro
    Zarain-Herzberg, Angel
    Avila, Guillermo
    JOURNAL OF PHYSIOLOGY-LONDON, 2017, 595 (13): : 4167 - 4187
  • [9] Oculopharyngeal muscular dystrophy as a paradigm for muscle aging
    Raz, Yotam
    Raz, Vered
    FRONTIERS IN AGING NEUROSCIENCE, 2014, 6
  • [10] Mutational analysis of the PABPN1 gene in oculopharyngeal muscular dystrophy
    Plata, Cristina
    Perez, Hector
    Lopez, Humberto
    Graue Moreno, Gerardo
    Astiazaran, Mirena
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2019, 60 (09)